Immune cell phenotypes as causal factors in liver disease progression revealed by Mendelian randomization

孟德尔随机化揭示免疫细胞表型是肝病进展的致病因素

阅读:1

Abstract

Immune cells are central mediators of the immune response and play critical roles in the pathogenesis and progression of liver diseases. Understanding the specific contributions of immune cells to liver disease progression is essential for developing targeted therapeutic strategies. In this study, we employed a two-sample Mendelian randomization (MR) approach to explore potential causal relationships between peripheral immune cell phenotypes and liver diseases, using genetic instrumental variables from large-scale genome-wide association studies (GWAS). Applying the inverse variance weighted (IVW) methods, we identified that monocyte count(odds ratio (OR) 0.81; 95% confidence interval (CI) 0.74-0.90; P  = 5.95 × 10(- 5), P(FDR) = 3.57 × 10(- 4)), CD3(-) lymphocyte/lymphocyte (OR 0.59, 95% CI 0.45-0.79; P  =  3.29 × 10(- 4), P(FDR) = 5.92 × 10(- 3)) and SSC-A (Side Scatter Area) on Natural Killer (NK) cells (OR 0.89, 95% CI 0.82-0.95; P  = 1.37 × 10(- 3), P(FDR) = 0.0396) acted as protective factors against alcoholic liver disease. Similarly, the trait HLA DR(++) monocyte/monocyte was associated with a lower risk of autoimmune hepatitis (OR 0.56, 95% CI 0.41-0.79; P  = 7.42 × 10(- 4), P(FDR) = 0.0475). Conversely, an elevated blood monocytic Myeloid-Derived Suppressor Cells (MDSCs) count was associated with a higher risk of chronic hepatitis (OR 1.23, 95% CI 1.11-1.37; P  =  1.13 × 10(- 4), P(FDR) = 1.58 × 10(- 3)). Similarly, higher levels of HLA DR on CD14(-) CD16(+) monocyte (OR 0.84, 95% CI 0.78-0.91; P  =  2.07 × 10(- 5), P(FDR) = 1.32 × 10(- 3)) conferred lower risk for cirrhosis of liver. In hepatic failure, CD39(+) resting CD4 regulatory T cell count (OR 0.85, 95% CI 0.79-0.92; P  =  1.70 × 10(- 5), P(FDR) = 5.25 × 10(- 3)) played a protective role and CD28(+) CD45RA- CD8(dim) T cell/CD8(dim) T cell (OR 1.14, 95% CI 1.06-1.22; P  =  2.63 × 10(- 4), P(FDR) = 0.0406) exhibited a risk function. Our findings highlight key immune pathways in liver disease progression and underscore potential immunomodulatory targets for future therapeutic interventions. Further research is warranted to clarify the mechanistic underpinnings of these associations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。